Elan news from FiercePharma
NewsTysabri to get new Euro label
The European Medicines Agency called for an update to product information for Biogen Idec and Elan's multiple sclerosis drug Tysabri, highlighting the risk of a potentially deadly brain infection.... Read more...
Tysabri may deliver 'sustained improvement'
Tysabri may have scored a big plus for drugmakers Biogen Idec and Elan. A trial of the multiple sclerosis treatment showed that it might... Read more...
FDA, Biogen mull Tysabri label changes
The FDA is huddling with Biogen Idec and Elan on amendments to Tysabri's label. The reason, of course, is the
Elan scouts Dublin-area sites for plant
SPOTLIGHT: Elan scouts Dublin-area sites for plantElan, Ireland's biggest drugmaker, is hunting the Dublin area for sites for a new $300 million manufacturing plant, with a location near its partner... Read more...
AZ, Amgen earnings flat; Shire sales leap
It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring... Read more...
'Cloud of risk' swells around Tysabri
The multiple sclerosis drug Tysabri has hit an obstacle on its... Read more...
Biogen CEO: Pharma too wimpy to deal
Biogen Idec CEO to Big Pharma: You just didn't have the guts to make a deal. In an interview with the Boston Globe this week, Biogen honcho Jim Mullen said major drug makers are more conservative... Read more...
FDA reviews safety of Bristol antibiotic
Call it a distant possible death warning. Prompted by a study suggesting the drug may increase the risk of death, FDA has embarked on a safety review of Maxipime, a Bristol-Myers Squibb antibiotic.... Read more...
Is Big Pharma souring on Biogen deal?
Remember last week's rumors that Big Pharma was poised to jump at the chance to bid for Biogen... Read more...
Pfizer among Biogen front-runners
Merger-watch fans, listen up. The Financial Times is reporting some tantalizing details about the bidding for Biogen Idec, the biotech based in
| Press ReleasesEU Panel Recommends Update For Elan, Biogen's Tysabri LabelEU Panel Recommends Update For Elan, Biogen's Tysabri Label ZURICH -(Dow Jones)- European Medicines Agency, an advisory body to the European drugs regulator, said Thursday it recommends an update of Read more >> First Multiple Myeloma Patient TreatedElan and Biogen Idec Initiate First Clinical Trial of TYSABRI® in Oncology First Multiple Myeloma Patient Treated CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--Sept. 5, 2008--Elan Read more >> |
Get more Elan coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
